For citations:

New indications for the use of pembrolizumab in Russia: the use of the drug in the 1st line of treatment of recurrent and metastatic head and neck squamous cell carcinoma in single mode and in combination with chemotherapy has been approved. Head and Neck Tumors (HNT). 2020;10(3):118-119. (In Russ.)